Trial Profile

Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms RAPIDA
Sponsors AbbVie

Most Recent Events

01 Nov 2017 Results evaluating the rapidity of onset of clinical response to ADA therapy presented at the 25th United European Gastroenterology Week
02 Feb 2017 Status changed from active, no longer recruiting to completed.
02 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com